ABSTRACT
Novel coronavirus (2019-nCoV) is the pathogen of COVID-19. Some severe cases may suffer from respiratory failure or even death, which poses a great challenge to global public health. 2019-nCoV proteins not only participate in virus proliferation, but also play an important role in antagonizing host innate immune response, especially interferon response. In this paper, 2019-nCoV proteins involved in regulating host interferon response and the complex interaction between 2019-nCoV and interferons were summarized, aiming to provide a theoretical reference for the prevention and control of COVID-19.
ABSTRACT
Objective@#To explore the relationship among osteopontin(OPN), Interleukin-17A(IL-17A), anti-MBP auto-antibody and autism spectrum disorder(ASD), and to provide the theoretical basis for the etiology and pathogenesis of ASD.@*Methods@#Forty autistic children and forty matched healthy children were enrolled in this case-control study. The levels of OPN, IL-17A, anti-MBP autoantibody in serum were measured by enzyme-linked immunosorbent assay (ELISA). The associations between those metabolic levels and the severity and intelligence of ASD children were performed by Pearson or Spearman correlation.@*Results@#Children with ASD had higher serum levels of OPN, IL-17A [(296.89±162.95),0.93] pg/mL compared to healthy control[(217.98±113.39), 0.62] pg/mL(P<0.05). Serum OPN, IL-17A, and anti-MBP auto-antibody levels in ASD group were not correlated with the scores of ABC, CARS, and PPVT(P>0.05). However, anti-MBP auto-antibodies level in children with ASD were positively correlated with OPN and IL-17A levels, respectively(r=0.35, 0.34, P<0.05).@*Conclusion@#It was obvious that the ASD children were found with neuroimmunologic abnormality, and the underlying mechanism needs to be further explored.
ABSTRACT
Human enterovirus 71 (EV71) is one of the major causative agent of hand,foot and mouth disease (HFMD) in infant.Clinical studies find that EV71 infection can cause a variety of clinical manifestations,from mild HFMD to fatal neurogenic pulmonary edema and even death,but the reasons remain unclear.The capsid protein VP1 of EV71 plays a key role in the processes of viral recognizing,binding and entering into the targeted cells and viral particles assembling.VP1 variation is a major determinant to EV71 fitness and immunogenicity.This study reviews the research progress of the structure,functions and associated antiviral vaccines and drugs of VP1,which further provides a theoretical basis for developing new and more effective antiviral vaccine and drugs.
ABSTRACT
Objective To investigate effect on patients with chronic heart failure complicated with euthyroid sick syndrome(ESS) who had given small dose of levothyroxine sodium that based on the routine anti heart failure therapy.Methods 70 patients with chronic cardiac insufficiency and ESS were randomly divided into control group and treatment group,the control group patients were given routine anti heart failure treatment,while the treatment group plus levothyroxine sodium tablets for 1year.Observe and compare the relevant examination and laboratory indexes of 2 groups before and after treatment,follow up the number of vascular events about 2 groups within 1year.Results The 6 minutes walk test [ Respectively:(383.0 ± 48.7 ) m,(339.3 ± 37.8 ) m ],NYHA heart function classification[ Respectively:(2.7 ± 0.4)grade,(3.2 ±0.5) grade],LVEF[ Respectively:(40.87 ± 8.18)％,(35.38 ± 7.35 ) ％ ],BNP [ Respectively:( 197.74 ± 20.58 ) ng/L,( 302.01 ± 10.15 ) ng/L ] water of the treatment group [Respectively:(317.0 ± 36.6)m,(323.4 ± 44.8)m,(3.5 ± 0.5) grade,(3.5 ± 0.3) grade,(33.18 ± 7.29)％,(34.74 ± 9.81 ) ％,( 369.75 ± 21.15 ) ng/L,(345.56 ± 18.65 ) ng/L] and the control group were better than before treatment.The treatment group was more significant,the two groups after treatment had a significant difference ( t=2.974,3.698,9.136,7.476,all P ＜ 0.05 ),the number of cardiovascular events of the treatment group was decreased within 1 year,compared with the control group the difference was statistically significant (x2 = 4.96,P ＜ 0.05 ).Conclusion In the treatment of conventional heart failure therapy combined with a small dose of levothyroxine sodium therapy on chronic heart failure patients can improve the patients' quality of life,reduce medical costs.